Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
about
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorderMultiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersGlutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatmentDrug treatment of obsessive-compulsive disorderComorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates TreatmentA selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forwardPharmacological treatments that facilitate extinction of fear: relevance to psychotherapy.Assessing the validity of current mouse genetic models of obsessive-compulsive disorder.Brain imaging in pediatric obsessive-compulsive disordermGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autismGlutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder.Evidence-based pharmacotherapy of obsessive-compulsive disorder.Role of lamotrigine augmentation in treatment-resistant obsessive compulsive disorder: a retrospective case review from South Asia.Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder.Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.Family-based genetic association study of DLGAP3 in Tourette Syndrome.Signal attenuation as a rat model of obsessive compulsive disorder.The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies.Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse geneticsPharmacotherapy of anxiety disorders: a critical reviewAssessment and management of treatment-refractory obsessive-compulsive disorder in children.Glutamate modulators in the treatment of obsessive-compulsive disorder.Glutamatergic agents for OCD and related disordersRiluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder.An update on the pharmacological treatment of obsessive-compulsive disorder.Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disordersGenetics of obsessive-compulsive disorder: a research update.Riluzole in psychiatry: a systematic review of the literature.Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial.Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive DisorderDiagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms.Management of obsessive-compulsive disorder comorbid with bipolar disorder.A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder.Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial.Long-term outcome in adults with obsessive-compulsive disorder.Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.Glutamate-based anxiolytic ligands in clinical trials.
P2860
Q24605193-E881CF82-8DB0-4313-8EC7-0B7866F6DB08Q24623179-66BF2792-1A07-41DA-8374-8267050D47B7Q24633004-08EAD8E6-DF34-486C-A4E4-F690B66DD4F3Q24635508-38B9552E-AC50-462A-B3C1-329587EC452DQ27015872-BFA6F11D-C91F-4372-B42A-0B4D84281A15Q28082048-35AFAA00-78A1-4FDF-818A-43A288EB8139Q28292137-6FC58080-CDA6-4638-9D54-C3B72B573CE5Q30480038-ECF8B2AA-A098-4726-9AAA-5AB718A0DCAEQ30482891-97D3C954-73EA-4638-A57A-B5B203EE1D70Q33373047-48D2AFDF-FAB7-4254-8C96-16B8AD375251Q34053492-F1B86C72-88D2-4EB0-98EA-C64CA5594C20Q34241062-EB4CA9AE-DCCA-48F1-8102-0F7C3A5206C7Q34245428-CDC5CED3-62CC-4485-BB82-37F19382FA28Q34476167-E9AF9D2E-8985-4BCB-A6D5-019E183845B6Q34594014-B53E1177-0858-40CE-B3E7-B6CAD48783C8Q34678136-5FD27E48-9FB5-4235-85F8-E8E8506AA40DQ34733335-C9D42CB2-9F15-4C66-9306-1C1AAE9A659AQ35161903-4E0D4B96-5202-42EF-B785-748ABB5BABCEQ35190052-3868E631-D13F-4B08-9F33-D5A1A2D093AAQ35341623-0951027F-7C28-42F6-AB30-88B1FA2DC20CQ35686859-C210B7DC-DE9A-4C22-9EA1-3F4A7BF1C706Q35697831-AE7A3F84-4C13-4C8F-8561-263C4D878B40Q35897264-7588D591-FBD0-4A12-8D25-30454A670336Q35967025-84D125DB-85BB-4267-850D-A938779B998EQ36029739-C6C0F0FF-E86F-45B2-96A1-B171B7D1B610Q36049118-865FB57A-962A-4CAD-9D8C-E6BDD1DC63D2Q36765772-5465048D-FBEC-4967-95DD-B301A4ACFAE3Q36873932-556369E3-FF8D-45B0-8BB7-4B36BB7DAF3CQ36902024-B342FAD8-BEA7-484C-952F-DFB5319B56CCQ36983354-D09DE4DA-7AD4-41C0-B248-AB0C5D709AD6Q37099618-51071223-277D-4E40-8FF1-82B596F15CFBQ37352930-4F976209-AF5D-48A0-BF1A-B3F664FA83DCQ37383381-AE160BB8-9D87-478E-AB5E-FDCB2263A69EQ37400532-7B1D6C38-4185-4F65-81F3-E3521D0A99E7Q37417627-AEF9814E-168A-4B77-AC61-321D33532037Q37582283-E3EA0219-3E22-4A4C-B320-D9A47365291AQ37598903-6B313A32-6556-4C0C-B20A-E4E9A29F893FQ37633750-E31F89F2-BA34-4567-969E-A5803B33DA53Q38004948-A1E35B6A-7AFC-4A46-8238-56D8DE551839Q38110306-105A97B8-C02D-4681-9F3B-7234FA4596C0
P2860
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@ast
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@en
type
label
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@ast
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@en
prefLabel
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@ast
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@en
P2860
P1433
P1476
Glutamate-modulating drugs as ...... obsessive-compulsive disorder.
@en
P2093
John H Krystal
Vladimir Coric
P2860
P356
10.1016/J.NURX.2005.12.006
P577
2006-01-01T00:00:00Z